Skip to main content
SpringerLink
Log in

Zellbasierte Therapeutika in der pädiatrischen Rheumatologie

  • Chapter
  • First Online:
Pädiatrische Rheumatologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 1375 Accesses

Zusammenfassung

Bei chronisch-entzündlichen Entzündung nehmen Entzündungszellen eine zentrale Rolle bei der Einleitung und Unterhaltung der inflammatorischen Reaktion ein. In diesem Kapitel werden Therapeutika vorgestellt, die direkt die Funktion der B- und T-Zellen verändern. Der monoklonale Antikörper Rituximab ist gegen das CD20-Molekül auf der Oberfläche von B-Zellen gerichtet und führt nach Bindung zur Zytotoxizität. Dieses Medikament ist im Kindesalter für die Granulomatose mit Polyangiitis und die mikroskopische Polyangiitis zugelassen. Der monoklonale Antikörper Belimumab ist gegen den B-Zell-Aktivierungsfaktor (BAFF oder BLyS) gerichtet und hat eine Zulassung für die Behandlung des aktiven, Autoantikörper-positiven kindlichen systemischem Lupus erythematodes. Das Fusionsprotein Abatacept (CTLA4-Ig) bindet mit hoher Affinität an das kostimulatorisch wirksame CD28 auf der Oberfläche von T-Zellen und unterbindet so deren IL-2-Produktion und Proliferation. Abatacept ist für die Behandlung der polyartikulären juvenilen idiopathischen Arthritis zugelassen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 229.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Brunner HI, Tzaribachev N, Vega-Cornejo G, Louw I, Berman A, Penades IC, Anton J, Avila-Zapata F, Cuttica R, Horneff G, Foeldvari I, Keltsev V, Kingsbury DJ, Viola DO, Joos R, Lauwerys B, Gastanaga MEP, Rama ME, Wouters C, Bohnsack J, Breedt J, Fischbach M, Lutz T, Minden K, Miraval T, Ally M, Rubio-Perez N, Gervais ES, van Zyl R, Li X, Nys M, Wong R, Banerjee S, Lovell DJ, Martini A, Ruperto N, O. Paediatric Rheumatology International Trials and G. the Pediatric Rheumatology Collaborative Study (2018) Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study. Arthritis Rheumatol 70(7):1144–1154

    Article  CAS  PubMed Central  Google Scholar 

  • Brunner HI, Abud-Mendoza C, Viola DO, Penades IC, Levy D, Anton J, Calderon JE, Chasnyk VG, Ferrandiz MA, Keltsev V, Gastanaga MEP, Shishov M, Boteanu AL, Henrickson M, Bass D, Clark K, Hammer A, Ji BN, Nino A, Roth DA, Struemper H, Wang ML, Martini A, Lovell D, Ruperto N, O. Paediatric Rheumatology International Trials and G. the Pediatric Rheumatology Collaborative Study (2020a) Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis 79(10):1340–1348

    Article  CAS  Google Scholar 

  • Brunner HI, Tzaribachev N, Cornejo GV, Joos R, Gervais E, Cimaz R, Penades IC, Cuttica R, Lutz T, Quartier P, Gandhi Y, Nys M, Wong R, Martini A, Lovell DJ, Ruperto N, G. Pediatric Rheumatology Collaborative Study and O. the Paediatric Rheumatology International Trials (2020b) Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2–5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. Pediatr Rheumatol Online J 18(1):19

    Article  PubMed Central  Google Scholar 

  • Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Porawska W, Box J, Legerton C 3rd, Nasonov E, Durez P, Aranda R, Pappu R, Delaet I, Teng J, Alten R (2011) Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 63(10):2854–2864

    Article  CAS  PubMed Central  Google Scholar 

  • Golay J, Semenzato G, Rambaldi A, Foa R, Gaidano G, Gamba E, Pane F, Pinto A, Specchia G, Zaja F, Regazzi M (2013) Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs 5(6):826–837

    Article  PubMed Central  Google Scholar 

  • Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Quemeneur T, Blanchard-Delaunay C, Godmer P, Puechal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, Ravaud P, Mouthon L, G. French Vasculitis Study (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371(19):1771–1780

    Article  Google Scholar 

  • Hassan SU, Md Yusof MY, Emery P, Dass S, Vital EM (2020) Biologic sequencing in systemic lupus erythematosus: after secondary non-response to rituximab, switching to humanised anti-CD20 agent is more effective than belimumab. Front Med (Lausanne) 7:498

    Article  Google Scholar 

  • Khojah AM, Miller ML, Klein-Gitelman MS, Curran ML, Hans V, Pachman LM, Fuleihan RL (2019) Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases. Pediatr Rheumatol Online J 17(1):61

    Article  PubMed Central  Google Scholar 

  • Kiykim A, Ogulur I, Dursun E, Charbonnier LM, Nain E, Cekic S, Dogruel D, Karaca NE, Cogurlu MT, Bilir OA, Cansever M, Kapakli H, Baser D, Kasap N, Kutlug S, Altintas DU, Al-Shaibi A, Agrebi N, Kara M, Guven A, Somer A, Aydogmus C, Ayaz NA, Metin A, Aydogan M, Uncuoglu A, Patiroglu T, Yildiran A, Guner SN, Keles S, Reisli I, Aksu G, Kutukculer N, Kilic SS, Yilmaz M, Karakoc-Aydiner E, Lo B, Ozen A, Chatila TA, Baris S (2019) Abatacept as a long-term targeted therapy for LRBA deficiency. J Allergy Clin Immunol Pract 7(8):2790–2800.e15

    Article  PubMed Central  Google Scholar 

  • Lovell DJ, Ruperto N, Mouy R, Paz E, Rubio-Perez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhaes C, Chavez-Corrales J, Huemer C, Kivitz A, Blanco FJ, Foeldvari I, Hofer M, Huppertz HI, Deslandre CJ, Minden K, Punaro M, Block AJ, Giannini EH, Martini A, G. Pediatric Rheumatology Collaborative Study and O. the Paediatric Rheumatology International Trials (2015) Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol 67(10):2759–2770

    Article  PubMed Central  Google Scholar 

  • Ma Y, Lin BR, Lin B, Hou S, Qian WZ, Li J, Tan M, Ma J, Li BH, Wang H, Wen AD, Guo YJ (2009) Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. Acta Pharmacol Sin 30(3):364–371

    Article  CAS  PubMed Central  Google Scholar 

  • Mahmoud I, Jellouli M, Boukhris I, Charfi R, Ben Tekaya A, Saidane O, Ferjani M, Hammi Y, Trabelsi S, Khalfallah N, Tekaya R, Gargah T, Abdelmoula L (2017) Efficacy and safety of rituximab in the management of pediatric systemic lupus erythematosus: a systematic review. J Pediatr 187(213–219):e212

    Google Scholar 

  • Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhaes C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH, Paediatric Rheumatology ITO, Pediatric Rheumatology Collaborative Study G (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372(9636):383–391

    Article  CAS  Google Scholar 

  • Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhaes C, Chavez-Corrales J, Huemer C, Kivitz A, Blanco FJ, Foeldvari I, Hofer M, Horneff G, Huppertz HI, Job-Deslandre C, Loy A, Minden K, Punaro M, Nunez AF, Sigal LH, Block AJ, Nys M, Martini A, Giannini EH, O. Paediatric Rheumatology International Trials and G. the Pediatric Rheumatology Collaborative Study (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 62(6):1792–1802

    Article  CAS  Google Scholar 

  • Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker JC, Lin C, Cornet PL, Dougados M (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67(8):1096–1103

    Article  CAS  Google Scholar 

  • Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, Clair EWS, Fessler BJ, Ding L, Viviano L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Mueller M, Sejismundo LP, Mieras K, Stone JH, R.-I. R. Group (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369(5):417–427

    Article  CAS  PubMed Central  Google Scholar 

  • Tappeiner C, Miserocchi E, Bodaghi B, Kotaniemi K, Mackensen F, Gerloni V, Quartier P, Lutz T, Heiligenhaus A (2015) Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 42(4):706–711

    Article  CAS  Google Scholar 

  • Tesch VK, Abolhassani H, Shadur B, Zobel J, Mareika Y, Sharapova S, Karakoc-Aydiner E, Riviere JG, Garcia-Prat M, Moes N, Haerynck F, Gonzales-Granado LI, Perez JLS, Mukhina A, Shcherbina A, Aghamohammadi A, Hammarstrom L, Dogu F, Haskologlu S, Ikinciogullari AI, Bal SK, Baris S, Kilic SS, Karaca NE, Kutukculer N, Girschick H, Kolios A, Keles S, Uygun V, Stepensky P, Worth A, van Montfrans JM, Peters AMJ, Meyts I, Adeli M, Marzollo A, Padem N, Khojah AM, Chavoshzadeh Z, Stefanija MA, Bakhtiar S, Florkin B, Meeths M, Gamez L, Grimbacher B, Seppanen MRJ, Lankester A, Gennery AR, Seidel MG, Errors CI, B. Registry Working Parties of the European Society for, T. Marrow and I. the European Society for (2020) Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score. J Allergy Clin Immunol 145(5):1452–1463

    Article  CAS  Google Scholar 

  • Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, Maldonado M, Fleischmann R (2013) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 65(1):28–38

    Article  CAS  PubMed Central  Google Scholar 

  • Wise LM, Stohl W (2020) Belimumab and rituximab in systemic lupus erythematosus: a tale of two B cell-targeting agents. Front Med (Lausanne) 7:303

    Article  Google Scholar 

  • Zhang J, Wan W, Miao L, Wu J, Dong J, Shen Y, Xiong C, Li C, Xue Y, Cao G, Ma P (2020) Pharmacokinetics, pharmacodynamics and safety of belimumab in Chinese patients with systemic lupus erythematosus: a phase I, open-label study. Rheumatol Ther 7(1):191–200

    Article  PubMed Central  Google Scholar 

  • Zulian F, Balzarin M, Falcini F, Martini G, Alessio M, Cimaz R, Cimino L, Zannin ME (2010) Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) 62(6):821–825

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Aachen, Aachen, Deutschland

    Norbert Wagner

  2. Klinik für Pädiatrie m.S. Pneumologie, Immunologie und Intensivmedizin, Charité – Universitätsmedizin Berlin, Berlin, Deutschland

    Tilmann Kallinich

  3. Sozialpädiatrisches Zentrum (SPZ), Charité – Universitätsmedizin Berlin, Berlin, Deutschland

    Tilmann Kallinich

Authors
  1. Norbert Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tilmann Kallinich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Norbert Wagner .

Editor information

Editors and Affiliations

  1. Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Aachen, Aachen, Deutschland

    Norbert Wagner

  2. Sektion Rheumatologie der Klinik für Pädiatrie m.S. Pneumologie, Immunologie und Intensivmedizin mit Bereich Rheumatologie, im Sozialpädiatrischen ZentrumCharité - Universitätsmedizin Berlin, Berlin, Deutschland

    Günther Dannecker

  3. Sektion Rheumatologie der Klinik für Pädiatrie m.S. Pneumologie, Immunologie und Intensivmedizin mit Bereich Rheumatologie, im Sozialpädiatrischen ZentrumCharité - Universitätsmedizin Berlin, Berlin, Deutschland

    Tilmann Kallinich

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wagner, N., Kallinich, T. (2022). Zellbasierte Therapeutika in der pädiatrischen Rheumatologie. In: Wagner, N., Dannecker, G., Kallinich, T. (eds) Pädiatrische Rheumatologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-60410-6_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-60410-6_19

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-60409-0

  • Online ISBN: 978-3-662-60410-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation